<table id="_RefID0E41AE" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1: Drugs that may have their plasma concentrations increased by itraconazole</caption>
<col width="20%"></col>
<col width="21%"></col>
<col width="19%"></col>
<col width="21%"></col>
<col width="22%"></col>
<thead>
<tr>
<th stylecode="Rrule Botrule Lrule Toprule ">
<content stylecode="bold">Drug Class</content>
</th>
<th stylecode="Rrule Botrule Toprule ">
<content stylecode="bold">Contraindicated</content>
</th>
<th stylecode="Rrule Botrule Toprule ">
<content stylecode="bold">Not Recommended</content>
</th>
<th stylecode="Rrule Botrule Toprule ">
<content stylecode="bold">Use with Caution</content>
</th>
<th stylecode="Rrule Botrule Toprule ">
<content stylecode="bold">Comments</content>
</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top"></td>
<td stylecode="Rrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Under no circumstances is the drug to be </content>
<content stylecode="italics">coadministered</content>
<content stylecode="italics"> with </content>
<content stylecode="italics">itraconazole</content>
<content stylecode="italics">, and up to two weeks after discontinuation of treatment with </content>
<content stylecode="italics">itraconazole</content>
<content stylecode="italics">.</content>
</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">It is recommended that the use of the drug be avoided during and up to two weeks after discontinuation of treatment with </content>
<content stylecode="italics">itraconazole</content>
<content stylecode="italics">, unless the benefits outweigh the potentially increased risks of side effects. If </content>
<content stylecode="italics">coadministration</content>
<content stylecode="italics"> cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage </content>
<content stylecode="italics">be</content>
<content stylecode="italics"> reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the </content>
<content stylecode="italics">coadministered</content>
<content stylecode="italics"> drug should be consulted for information on dose adjustment and adverse effects.</content>
</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Careful monitoring is recommended when the drug is </content>
<content stylecode="italics">coadministered</content>
<content stylecode="italics"> with </content>
<content stylecode="italics">itraconazole</content>
<content stylecode="italics">. Upon </content>
<content stylecode="italics">coadministration</content>
<content stylecode="italics">, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the </content>
<content stylecode="italics">coadministered</content>
<content stylecode="italics"> drug should be consulted for information on dose adjustment and adverse effects.</content>
</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Alpha Blockers</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>tamsulosin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule " valign="top">
<paragraph>Analgesics</paragraph>
</td>
<td stylecode="Rrule " valign="top">
<paragraph>methadone</paragraph>
</td>
<td stylecode="Rrule " valign="top"></td>
<td stylecode="Rrule " valign="top">
<paragraph>alfentanil, <br/>buprenorphine IV and sublingual, <br/>fentanyl, <br/>oxycodone, <br/>sufentanil</paragraph>
</td>
<td stylecode="Rrule " valign="top">
<paragraph>
<content stylecode="bold">Methadone:</content> The potential increase in plasma concentrations of methadone when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule " valign="top"></td>
<td stylecode="Rrule " valign="top"></td>
<td stylecode="Rrule " valign="top"></td>
<td stylecode="Rrule " valign="top"></td>
<td stylecode="Rrule " valign="top">
<paragraph>
<content stylecode="bold">Fentanyl: </content>The potential increase in plasma concentrations of fentanyl when coadministered with itraconazole may increase the risk of potentially fatal respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Sufentanil</content>
<content stylecode="bold">: </content>No human pharmacokinetic data of an interaction with itraconazole are available. In vitro data suggest that sufentanil is metabolized by CYP3A4 and so potentially increased sufentanil plasma concentrations would be expected when coadministered with itraconazole.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antiarrhythmics</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>disopyramide, <br/>dofetilide, <br/>dronedarone, <br/>quinidine</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>digoxin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Disopyramide</content>
<content stylecode="bold">, </content>
<content stylecode="bold">dofetilide</content>
<content stylecode="bold">, </content>
<content stylecode="bold">dronedarone</content>
<content stylecode="bold">, quinidine:</content> The potential increase in plasma concentrations of these drugs when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antibacterials</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>telithromycin, in subjects with severe renal impairment or severe hepatic impairment</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>rifabutin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>telithromycin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Telithromycin</content>
<content stylecode="bold">: </content>The potential increase in plasma concentrations of telithromycin in subjects with severe renal impairment or severe hepatic impairment, when coadministered with itraconazole may increase the risk of serious cardiovascular events including QT prolongation and torsade de pointes.</paragraph>
<paragraph>
<content stylecode="bold">Rifabutin</content>
<content stylecode="bold">:</content> See also under '<linkhtml href="#ID_873f020d-fa15-4729-a9a4-94e03e8f2e7e">Drugs that may decrease itraconazole plasma concentrations</linkhtml>'.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Anticoagulants and Antiplatelet Drugs</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>ticagrelor</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>apixaban, rivaroxaban</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>coumarins, <br/>cilostazol, <br/>dabigatran</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Ticagrelor</content>
<content stylecode="bold">: </content>The potential increase in plasma concentrations of ticagrelor may increase the risk of bleeding.</paragraph>
<paragraph>
<content stylecode="bold">Coumarins</content>
<content stylecode="bold">:</content> Itraconazole may enhance the anticoagulant effect of coumarin-like drugs, such as warfarin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Anticonvulsants</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>carbamazepine</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Carbamazepine: </content>
<content stylecode="italics">In vivo</content> studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and itraconazole, concomitant administration of itraconazole and carbamazepine may inhibit the metabolism of carbamazepine. See also under '<linkhtml href="#ID_873f020d-fa15-4729-a9a4-94e03e8f2e7e">Drugs that may decrease itraconazole plasma concentrations</linkhtml>'.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antidiabetics</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>repaglinide, <br/>saxagliptin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antihelmintics and Antiprotozoals</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>praziquantel</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antimigraine Drugs</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>ergot alkaloids, such as dihydroergotamine, <br/>ergometrine (ergonovine), <br/>ergotamine, <br/>methylergometrine (methylergonovine)</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>eletriptan</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Ergot Alkaloids:</content> The potential increase in plasma concentrations of ergot alkaloids when coadministered with itraconazole may increase the risk of ergotism, i.e., a risk for vasospasm potentially leading to cerebral ischemia and/or ischemia of the extremities.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antineoplastics</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>irinotecan</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>axitnib,<br/>dabrafenib,<br/>dasatinib, <br/>ibrutinib,<br/>nilotinib,<br/>sunitinib</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>bortezomib, <br/>busulphan, <br/>docetaxel, <br/>erlotinib, <br/>imatinib,<br/>ixabepilone, <br/>lapatinib, <br/>ponatinib,<br/>trimetrexate, <br/>vinca alkaloids</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Irinotecan:</content> The potential increase in plasma concentrations of irinotecan when coadministered with itraconazole may increase the risk of potentially fatal adverse events.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule " valign="top">
<paragraph>Antipsychotics, Anxiolytics and Hypnotics</paragraph>
</td>
<td stylecode="Rrule " valign="top">
<paragraph>lurasidone, <br/>oral midazolam, <br/>pimozide, <br/>triazolam</paragraph>
</td>
<td stylecode="Rrule " valign="top"></td>
<td stylecode="Rrule " valign="top">
<paragraph>alprazolam, <br/>aripiprazole, <br/>buspirone, <br/>diazepam, <br/>haloperidol, <br/>midazolam IV, <br/>perospirone, <br/>quetiapine, <br/>ramelteon, <br/>risperidone</paragraph>
</td>
<td stylecode="Rrule " valign="top">
<paragraph>
<content stylecode="bold">Midazolam, </content>
<content stylecode="bold">triazolam</content>: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Pimozide</content>
<content stylecode="bold">:</content> The potential increase in plasma concentrations of pimozide when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antivirals</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>simeprevir</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>maraviroc, <br/>indinavir, <br/>ritonavir,</paragraph>
<paragraph>saquinavir</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Indinavir</content>
<content stylecode="bold">, ritonavir:</content> See also under '<linkhtml href="#ID_31f4af74-e73d-4d2f-8084-524fedbcf1d0">Drugs that may increase itraconazole plasma concentrations</linkhtml>'.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Beta Blockers</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>nadolol</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Calcium Channel Blockers</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>felodipine, <br/>nisoldipine</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>other dihydropyridines, <br/>verapamil</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Calcium channel blockers</content> can have a negative inotropic effect which may be additive to those of itraconazole. The potential increase in plasma concentrations of calcium channel blockers when co-administered with itraconazole may increase the risk of congestive heart failure. </paragraph>
<paragraph>
<content stylecode="bold">Dihydropyridines</content>
<content stylecode="bold">:</content> Concomitant administration of itraconazole may cause several-fold increases in plasma concentrations of dihydropyridines. Edema has been reported in patients concomitantly receiving itraconazole and dihydropyridine calcium channel blockers.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Cardiovascular Drugs, Miscellaneous</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>ranolazine</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>aliskiren,<br/>sildenafil, for the treatment of pulmonary hypertension</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>bosentan,<br/>riociguat</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Ranolazine</content>
<content stylecode="bold">:</content> The potential increase in plasma concentrations of ranolazine when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Diuretics</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>eplerenone</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Eplerenone</content>
<content stylecode="bold">:</content> The potential increase in plasma concentrations of eplerenone when coadministered with itraconazole may increase the risk of hyperkalemia and hypotension.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Gastrointestinal Drugs</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>cisapride</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>aprepitant</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Cisapride</content>
<content stylecode="bold">:</content> The potential increase in plasma concentrations of cisapride when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Immunosuppressants</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>everolimus, <br/>temsirolimus</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>budesonide, <br/>ciclesonide, <br/>cyclosporine, <br/>dexamethasone, <br/>fluticasone, <br/>methylprednisolone,<br/>rapamycin (also known as sirolimus), <br/>tacrolimus</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Lipid Regulating Drugs</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>lovastatin, <br/>simvastatin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>atorvastatin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>The potential increase in plasma concentrations of atorvastatin, lovastatin, and simvastatin when coadministered with itraconazole may increase the risk of skeletal muscle toxicity, including rhabdomyolysis.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Respiratory Drugs</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>salmeterol</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top"></td>
<td stylecode="Rrule Botrule " valign="top"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Urological Drugs</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>fesoterodine, in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, solifenacin, in subjects with severe renal impairment or moderate to severe hepatic impairment</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>darifenacin,<br/>vardenafil</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>fesoterodine, <br/>oxybutynin,<br/>sildenafil, for the treatment of erectile dysfunction,<br/>solifenacin, <br/>tadalafil, <br/>tolterodine</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Fesoterodine</content>
<content stylecode="bold">:</content> The potential increase in plasma concentrations of the fesoterodine active metabolite may be greater in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, which may lead to an increased risk of adverse reactions.<br/>Solifenacin: The potential increase in plasma concentrations of solifenacin in subjects with severe renal impairment or moderate to severe hepatic impairment, when coadministered with itraconazole may increase the risk of serious cardiovascular events including QT prolongation.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Other</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>colchicine, in subjects with renal or hepatic impairment</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>colchicine,<br/>conivaptan,<br/>tolvaptan</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>cinacalcet</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Colchicine:</content> The potential increase in plasma concentrations of colchicine when coadministered with itraconazole may increase the risk of potentially fatal adverse events.<br/>
<content stylecode="bold">Conivaptan</content>
<content stylecode="bold"> and </content>
<content stylecode="bold">Tolvaptan</content>
<content stylecode="bold">:</content> A safe and effective dose of either conivaptan or tolvaptan has not been established when coadministered with itraconazole.</paragraph>
</td>
</tr>
</tbody>
</table>